#None #Insmed #CHEST 2026 #IDWeek 2026

Insmed Reveals New Insights Ahead of Major Conferences

Insmed Incorporated, a biopharmaceutical innovator, is set to showcase pivotal data from its respiratory portfolio at two prominent medical conferences: the American College of Chest Physicians Annual Meeting (CHEST 2026) and IDWeek 2026. Scheduled for October 18-21 and October 21-24, respectively, these events will highlight the company’s research on treatments for serious diseases, particularly focused on respiratory conditions.

Recent Developments at Insmed

This autumn promises essential insights into several groundbreaking therapies. Insmed will unveil three late-breaking abstracts at CHEST 2026 that enhance understanding of Treprostinil Palmitil Inhalation Powder (TPIP), an innovative treatment targeted at Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Moreover, additional data from the Phase 3 ASPEN study will address management strategies for Bronchiectasis, offering new perspectives on patient care.

Martina Flammer, M.D., and Chief Medical Officer of Insmed, emphasized the significance of these new findings: “This fall medical congress season serves as a powerful reminder of what’s possible when we commit to developing meaningful solutions for patients in need. Our presentations at CHEST and IDWeek epitomize our dedication to advancing critical therapies that can greatly improve our target patient populations.”

Significant Presentations Scheduled

At CHEST 2026

• - Highlighting TPIP: Three critical abstracts will be presented on the clinical development of TPIP, focusing on its efficacy for both PAH and PH-ILD treatments. This includes:

- Functional Respiratory Imaging Correlation with TPIP Treatment: This presentation aims to elucidate how TPIP treatment correlates with clinical outcomes in PAH patients. Scheduled for October 20, 2026.
- Open-Label Extension Study of TPIP: This study presents one-year data from patient trials and will contribute invaluable information regarding the sustained effects of TPIP.
- Patient-Reported Outcomes in Bronchiectasis: An analysis from the ASPEN trial focusing on sputum color and its link to neutrophil serine proteases.

At IDWeek 2026

Insmed will explore two important abstracts regarding ARIKAYCE, a treatment for Mycobacterium Avium complex (MAC) lung disease:

• - Amikacin and Macrolide Resistance: Examining resistance development in MAC patients based on the ENCORE study outcomes.
• - Real-World Evidence on MAC Lung Disease: A presentation detailing treatment drivers and patient outcomes concerning MAC lung disease.

About the Drugs in Focus

Treprostinil Palmitil Inhalation Powder (TPIP)

TPIP is an investigational drug designed as a dry powder formulation aimed at providing innovative therapy for patients suffering from PAH. In this formulation, Treprostinil is combined with a 16-carbon chain, enhancing its delivery directly into the lungs. The goal here is to establish a once-daily treatment method making it potentially beneficial for patients with various pulmonary conditions.

ARIKAYCE®

ARIKAYCE is an inhaled form of amikacin, addressing difficult-to-treat MAC lung disease. By utilizing PULMOVANCE™ liposomal technology, this treatment directly targets lung macrophages while reducing systemic exposure. The current guidelines recommend it for suitable patient groups, showcasing its vital role in managing MAC lung disease.

Conclusion

The upcoming presentations at CHEST 2026 and IDWeek 2026 denote critical advancements in the realm of respiratory therapy that Insmed is pioneering. By emphasizing the potential of treatments like TPIP and ARIKAYCE, Insmed is committed to transforming the lives of patients facing severe respiratory diseases. The company’s presence at these conferences offers a reassuring promise of continued innovation and dedication to patient care in the medical community.